

Helena Rebelo-de-Andrade

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2460590/publications.pdf>

Version: 2024-02-01

39
papers

1,375
citations

471061

17
h-index

344852

36
g-index

39
all docs

39
docs citations

39
times ranked

2199
citing authors

#	ARTICLE	IF	CITATIONS
1	Revision of clinical case definitions: influenza-like illness and severe acute respiratory infection. Bulletin of the World Health Organization, 2018, 96, 122-128.	1.5	205
2	Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014â€“2015. Antiviral Research, 2016, 132, 178-185.	1.9	155
3	Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013â€“2014. Antiviral Research, 2015, 117, 27-38.	1.9	132
4	Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015â€“2016. Antiviral Research, 2017, 146, 12-20.	1.9	87
5	Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012â€“2013. Antiviral Research, 2014, 110, 31-41.	1.9	85
6	Influenza vaccination in 22 developed countries: an update to 1995. Vaccine, 1997, 15, 1506-1511.	1.7	73
7	Transplacental transfer of measles and total IgG. Epidemiology and Infection, 1999, 122, 273-279.	1.0	69
8	Excess Mortality Associated with Influenza Epidemics in Portugal, 1980 to 2004. PLoS ONE, 2011, 6, e20661.	1.1	68
9	Influenza vaccination in 18 developed countries, 1980-1992. Vaccine, 1995, 13, 623-627.	1.7	62
10	High Genetic Diversity of Measles Virus, World Health Organization European Region, 2005â€“2006. Emerging Infectious Diseases, 2008, 14, 107-114.	2.0	59
11	Outbreak of Acute Respiratory Infection among Infants in Lisbon, Portugal, Caused by Human Adenovirus Serotype 3 and a New 7/3 Recombinant Strain. Journal of Clinical Microbiology, 2010, 48, 1391-1396.	1.8	46
12	Molecular characterization of the HA gene of influenza type B viruses. Journal of Medical Virology, 2005, 77, 541-549.	2.5	34
13	Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe. Journal of Clinical Virology, 2013, 57, 5-12.	1.6	27
14	Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike. Computational and Structural Biotechnology Journal, 2020, 18, 2117-2131.	1.9	27
15	Population genetics of IFITM3 in Portugal and Central Africa reveals a potential modifier of influenza severity. Immunogenetics, 2018, 70, 169-177.	1.2	21
16	Different diagnostic methods for detection of influenza epidemics. Epidemiology and Infection, 2000, 124, 515-522.	1.0	20
17	Analysis of influenza A H3N2 strains isolated in England during 1995â€“1996 using polymerase chain reaction restriction. Journal of Medical Virology, 1997, 51, 234-241.	2.5	19
18	Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs. Journal of Medical Virology, 2015, 87, 45-56.	2.5	18

#	ARTICLE	IF	CITATIONS
19	Antiviral drug profile of seasonal influenza viruses circulating in Portugal from 2004/2005 to 2008/2009 winter seasons. <i>Antiviral Research</i> , 2010, 86, 128-136.	1.9	16
20	Bronchiolitis Caused by Respiratory Syncytial Virus in an Area of Portugal: Epidemiology, Clinical Features, and Risk Factors. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2004, 23, 39-45.	1.3	15
21	Genomic signatures and antiviral drug susceptibility profile of A(H1N1)pdm09. <i>Journal of Clinical Virology</i> , 2012, 53, 140-144.	1.6	15
22	The 1918-1919 Influenza Pandemic in Portugal: A Regional Analysis of Death Impact. <i>American Journal of Epidemiology</i> , 2018, 187, 2541-2549.	1.6	14
23	To hit or not to hit: Large-scale sequence analysis and structure characterization of influenza A NS1 unlocks new antiviral target potential. <i>Virology</i> , 2019, 535, 297-307.	1.1	14
24	COMPARISON OF A COMMERCIAL ENZYME IMMUNOASSAY WITH PLAQUE REDUCTION NEUTRALIZATION FOR MATERNAL AND INFANT MEASLES ANTIBODY MEASUREMENT. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 1999, 41, 21-26.	0.5	11
25	Reverse genetics vaccine seeds for influenza: Proof of concept in the source of PB1 as a determinant factor in virus growth and antigen yield. <i>Virology</i> , 2016, 496, 21-27.	1.1	10
26	Antibody response to the influenza vaccine in healthcare workers. <i>Vaccine</i> , 2012, 30, 436-441.	1.7	9
27	Distinct kinetics and pathways of apoptosis in influenza A and B virus infection. <i>Virus Research</i> , 2015, 205, 33-40.	1.1	9
28	Heterogeneous influenza activity across Europe during the winter of 2002-2003. <i>Eurosurveillance</i> , 2003, 8, 230-239.	3.9	9
29	Heterogeneous Selective Pressure Acting on Influenza B Victoria- and Yamagata-Like Hemagglutinins. <i>Journal of Molecular Evolution</i> , 2008, 67, 427-435.	0.8	7
30	Molecular footprints of selective pressure in the neuraminidase gene of currently circulating human influenza subtypes and lineages. <i>Virology</i> , 2018, 522, 122-130.	1.1	7
31	Genetic evolution of PB1 in the zoonotic transmission of influenza A(H1) virus. <i>Infection, Genetics and Evolution</i> , 2014, 27, 234-243.	1.0	6
32	NS1 protein as a novel anti-influenza target: Map-and-mutate antiviral rationale reveals new putative druggable hot spots with an important role on viral replication. <i>Virology</i> , 2022, 565, 106-116.	1.1	6
33	COVID-19: impact on Public Health and hypothesis-driven investigations on genetic susceptibility and severity. <i>Immunogenetics</i> , 2022, 74, 381-407.	1.2	5
34	Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2. <i>Pharmaceutics</i> , 2022, 14, 877.	2.0	5
35	Characterization of influenza A/Fujian/411/2002(H3N2)-like viruses isolated in Portugal between 2003 and 2005. <i>Journal of Medical Virology</i> , 2008, 80, 1624-1630.	2.5	4
36	Association between chronic stress and immune response to influenza vaccine in healthcare workers. <i>Revista Portuguesa De Saude Publica</i> , 2014, 32, 18-26.	0.3	3

#	ARTICLE	IF	CITATIONS
37	Optimization of A(H1N1)pdm09 vaccine seed viruses: The source of PB1 and HA vRNA as a major determinant for antigen yield. <i>Virus Research</i> , 2022, 315, 198795.	1.1	2
38	Adaptive evolution on HA1 subunit of influenza B virus. <i>International Congress Series</i> , 2004, 1263, 691-694.	0.2	1
39	Genetic analysis of HA1 subunit of the haemagglutinin of influenza B viruses isolated in Portugal from 1994 to 2003. <i>International Congress Series</i> , 2004, 1263, 699-703.	0.2	0